FCF Fox Company Finance GmbH is delighted to publish the brand new “FCF Healthcare & Life Sciences Enterprise Capital Monitor – Europe 07/2024”.
The Monitor is a month-to-month revealed overview of enterprise capital tendencies within the European Healthcare & Life Sciences sector.
As of the tip of July 2025 we recognized the next present VC tendencies in Europe:
- Complete Healthcare & Life Sciences funding reached EUR 6,654m (+18% vs. 2024)
- Biotech/Pharma obtained 41% of the overall funding quantity (EUR 2,704m) with oncology being the main indication (23% of BioTech)
- In July, Nuclidium (Switzerland) secured the very best transaction quantity with EUR 84m, adopted by Artios (Nice Britain) with EUR 70m and Ultromics (Nice Britain) with EUR 50m
- GV (United States) is probably the most lively investor (by deal quantity in 2025), adopted by Alphabet (United States) and Thrive Capital (United States)
To entry the complete report, please click on right here.
By Mathias Klozenbücher and Johannes Hyperlink